OSLO, Norway, Nov. 16, 2018
OSLO, Norway, Nov. 16, 2018 /PRNewswire/ -- A individual participant in Nordic Nanovector ASA's (the "Company") (OSE:NANO) previous share option program, not being a primary insider, has exercised a total number of 300,000 options through exercise of a corresponding number of free-standing warrants. 185,421 of the options are exercised at a strike price of NOK 25 per share, and 114,579 of the options are exercised at a strike price of NOK 14.24 per share. Each free-standing warrant gives the right to receive one share in the Company.
Following exercise of the 300,000 free-standing warrants, the Company's registered share capital was increased by NOK 60,000 through issuance of 300,000 new shares, each with a nominal value of NOK 0.20, against payment of a total subscription price of NOK 6,267,130. Following the share capital increase the Company has a share capital of NOK 9,884,503 divided on 49,422,515 shares, each with a par value of NOK 0.20.
For further information, please contact:
VP Investor Relations and Corporate Communications
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information about the Company can be found at www.nordicnanovector.com
This information is subject to a duty of disclosure pursuant to Section 5-12 of the Norwegian Securities Trading Act.
This information was brought to you by Cision http://news.cision.com